Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation StudyNewsfile Corp • 04/11/24
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual MeetingNewsfile Corp • 03/28/24
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal DiseasesNewsfile Corp • 03/25/24
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the EyeNewsfile Corp • 03/08/24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 MillionNewsfile Corp • 01/31/24
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial RoyaltiesNewsfile Corp • 01/31/24
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis PigmentosaNewsfile Corp • 11/09/23
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis PigmentosaNewsfile Corp • 11/04/23
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor ConferenceNewsfile Corp • 10/16/23
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaNewsfile Corp • 10/03/23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsNewsfile Corp • 09/21/23
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis PigmentosaNewsfile Corp • 09/18/23
Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis PigmentosaNewsfile Corp • 09/14/23
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27Newsfile Corp • 09/01/23
Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal DiseasesNewsfile Corp • 08/29/23
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious UveitisNewsfile Corp • 08/23/23
Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness ProgramNewsfile Corp • 08/22/23
Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceNewsfile Corp • 08/16/23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development ProgressNewsfile Corp • 08/08/23
Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia TreatmentNewsfile Corp • 08/03/23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of DirectorsNewsfile Corp • 08/01/23